Current and future antimicrobial treatment of gonorrhoea – the rapidly evolving Neisseria gonorrhoeae continues to challenge
暂无分享,去创建一个
[1] M. Unemo,et al. Recommended antimicrobial treatment of uncomplicated gonorrhoea in 2009 in 11 East European countries: implementation of a Neisseria gonorrhoeae antimicrobial susceptibility programme in this region is crucial , 2010, Sexually Transmitted Infections.
[2] D. Yong,et al. Trends in Antimicrobial Resistance of Neisseria gonorrhoeae Isolated From Korean Patients From 2000 to 2006 , 2011, Sexually transmitted diseases.
[3] M. Unemo,et al. Treatment failure with 2 g of azithromycin (extended-release formulation) in gonorrhoea in Japan caused by the international multidrug-resistant ST1407 strain of Neisseria gonorrhoeae. , 2014, The Journal of antimicrobial chemotherapy.
[4] M. Falagas,et al. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. , 2009, Current drug metabolism.
[5] M. Unemo,et al. Is Neisseria gonorrhoeae Initiating a Future Era of Untreatable Gonorrhea?: Detailed Characterization of the First Strain with High-Level Resistance to Ceftriaxone , 2011, Antimicrobial Agents and Chemotherapy.
[6] H. Tan,et al. Estimating the population size of men who have sex with men: a modified Laska, Meisner and Siegel procedure taking into account internet populations , 2012, Sexually Transmitted Infections.
[7] M. Unemo,et al. High In Vitro Susceptibility to the Novel Spiropyrimidinetrione ETX0914 (AZD0914) among 873 Contemporary Clinical Neisseria gonorrhoeae Isolates from 21 European Countries from 2012 to 2014 , 2015, Antimicrobial Agents and Chemotherapy.
[8] G. Horsman,et al. Whole-Genome Phylogenomic Heterogeneity of Neisseria gonorrhoeae Isolates with Decreased Cephalosporin Susceptibility Collected in Canada between 1989 and 2013 , 2014, Journal of Clinical Microbiology.
[9] M. Unemo,et al. Antimicrobial susceptibility and genetic characteristics of Neisseria gonorrhoeae isolates from Vietnam, 2011 , 2013, BMC Infectious Diseases.
[10] M. Unemo,et al. Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[11] F. Martinson,et al. Neisseria gonorrhoeae Antimicrobial Susceptibility in Lilongwe, Malawi, 2007 , 2010, Sexually transmitted diseases.
[12] G. Hogg,et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. , 2013, The Journal of antimicrobial chemotherapy.
[13] W. Mogabgab,et al. Oral Cefixime Versus Intramuscular Ceftriaxone in Patients with Uncomplicated Gonococcal Infections , 1992, Sexually transmitted diseases.
[14] P. Read,et al. One confirmed and one suspected case of pharyngeal gonorrhoea treatment failure following 500mg ceftriaxone in Sydney, Australia. , 2013, Sexual health.
[15] J. Wasserheit,et al. The emerging threat of untreatable gonococcal infection. , 2012, The New England journal of medicine.
[16] M. Unemo,et al. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future , 2014, Clinical Microbiology Reviews.
[17] C Bignell,et al. UK national guideline for the management of gonorrhoea in adults, 2011 , 2011, International journal of STD & AIDS.
[18] C. del Rio,et al. Population structure of Neisseria gonorrhoeae based on whole genome data and its relationship with antibiotic resistance , 2015, PeerJ.
[19] M. Unemo,et al. Antimicrobial resistance, genetic resistance determinants for ceftriaxone and molecular epidemiology of Neisseria gonorrhoeae isolates in Nanjing, China. , 2014, The Journal of antimicrobial chemotherapy.
[20] M. Unemo,et al. Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae , 2009, Expert review of anti-infective therapy.
[21] K. Sankar,et al. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[22] I. Martin,et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. , 2013, JAMA.
[23] D. Whiley,et al. Two cases of failed ceftriaxone treatment in pharyngeal gonorrhoea verified by molecular microbiological methods. , 2009, Journal of medical microbiology.
[24] Josefina Ayats,et al. Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. , 2012, The Journal of antimicrobial chemotherapy.
[25] I. Kobayashi,et al. Analysis of mutations within multiple genes associated with resistance in a clinical isolate of Neisseria gonorrhoeae with reduced ceftriaxone susceptibility that shows a multidrug-resistant phenotype. , 2006, International journal of antimicrobial agents.
[26] T. Wong,et al. Canadian guidelines on sexually transmitted infections, 2006 , 2007, Canadian Medical Association Journal.
[27] M. Unemo,et al. Detailed characterization of the first high-level azithromycin-resistant Neisseria gonorrhoeae cases in Ireland. , 2015, The Journal of antimicrobial chemotherapy.
[28] O. Soge,et al. Failure of azithromycin 2.0 g in the treatment of gonococcal urethritis caused by high-level resistance in California. , 2015, Sexually transmitted diseases.
[29] M. Meltzer,et al. Optimizing Treatment of Antimicrobial-resistant Neisseria gonorrhoeae , 2005, Emerging infectious diseases.
[30] M. Unemo,et al. First Three Neisseria gonorrhoeae Isolates with High-Level Resistance to Azithromycin in Sweden: a Threat to Currently Available Dual-Antimicrobial Regimens for Treatment of Gonorrhea? , 2013, Antimicrobial Agents and Chemotherapy.
[31] P. Stefanelli,et al. Azithromycin-resistant Neisseria gonorrhoeae strains recently isolated in Italy. , 2009, The Journal of antimicrobial chemotherapy.
[32] I. Phillips,et al. Spectinomycin resistant gonococci. , 1983, British medical journal.
[33] M. Unemo,et al. In vitro activities of the novel bicyclolides modithromycin (EDP-420, EP-013420, S-013420) and EDP-322 against MDR clinical Neisseria gonorrhoeae isolates and international reference strains. , 2015, The Journal of antimicrobial chemotherapy.
[34] M. Unemo,et al. High-Level Cefixime- and Ceftriaxone-Resistant Neisseria gonorrhoeae in France: Novel penA Mosaic Allele in a Successful International Clone Causes Treatment Failure , 2011, Antimicrobial Agents and Chemotherapy.
[35] H. Furrer,et al. In Vitro Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin against Clinical Neisseria gonorrhoeae Isolates , 2014, Antimicrobial Agents and Chemotherapy.
[36] N. Low,et al. Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable Gonorrhoea , 2014, PLoS medicine.
[37] D. Mak,et al. Non-culture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. , 2014, The Journal of antimicrobial chemotherapy.
[38] M. Unemo,et al. Current and future treatment options for gonorrhoea , 2013, Sexually Transmitted Infections.
[39] M. Unemo,et al. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults , 2013, International journal of STD & AIDS.
[40] A Stary,et al. First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[41] L. Duley,et al. The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review , 2014, Systematic Reviews.
[42] M. Bala,et al. Monitoring antimicrobial resistance in Neisseria gonorrhoeae in selected countries of the WHO South-East Asia Region between 2009 and 2012: a retrospective analysis , 2013, Sexually Transmitted Infections.
[43] M. Unemo,et al. In Vitro Activity of Ertapenem versus Ceftriaxone against Neisseria gonorrhoeae Isolates with Highly Diverse Ceftriaxone MIC Values and Effects of Ceftriaxone Resistance Determinants: Ertapenem for Treatment of Gonorrhea? , 2012, Antimicrobial Agents and Chemotherapy.
[44] D. Nix,et al. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation. , 2010, The Journal of antimicrobial chemotherapy.
[45] J. Tapsall. Implications of current recommendations for third-generation cephalosporin use in the WHO Western Pacific Region following the emergence of multiresistant gonococci , 2009, Sexually Transmitted Infections.
[46] M. Unemo,et al. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. , 2011, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[47] M. Unemo,et al. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. , 2012, Future microbiology.
[48] W. Bowie,et al. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men , 1990, Antimicrobial Agents and Chemotherapy.
[49] M. Unemo. The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy. , 2012, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[50] M. Moyer,et al. Cefixime in the Treatment of Uncomplicated Gonorrhea , 1992, Sexually transmitted diseases.
[51] C. Ison. Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment , 2012, Current opinion in infectious diseases.
[52] Magnus Unemo,et al. Identification of Amino Acids Conferring High-Level Resistance to Expanded-Spectrum Cephalosporins in the penA Gene from Neisseria gonorrhoeae Strain H041 , 2013, Antimicrobial Agents and Chemotherapy.
[53] M. Unemo,et al. Future treatment of gonorrhoea – novel emerging drugs are essential and in progress? , 2015, Expert Opinion on Emerging Drugs.
[54] Hyo Jin Kim,et al. Emergence of decreased susceptibility and resistance to extended-spectrum cephalosporins in Neisseria gonorrhoeae in Korea. , 2015, The Journal of antimicrobial chemotherapy.
[55] M. Pandori,et al. Neisseria gonorrhoeae and extended-spectrum cephalosporins in California: surveillance and molecular detection of mosaic penA , 2013, BMC Infectious Diseases.
[56] M. Ohnishi,et al. Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. , 2012, The Journal of antimicrobial chemotherapy.
[57] M. Golden,et al. Potential Deleterious Effects of Promoting the Use of Ceftriaxone in the Treatment of Neisseria gonorrhoeae , 2014, Sexually transmitted diseases.
[58] M. Unemo,et al. Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[59] J. Rowley,et al. Global incidence and prevalence of selected curable sexually transmitted infections: 2008 , 2012 .
[60] J. Kaldor,et al. Molecular approaches to enhance surveillance of gonococcal antimicrobial resistance , 2014, Nature Reviews Microbiology.
[61] G. Burstein,et al. Sexually transmitted diseases treatment guidelines , 2003, Current opinion in pediatrics.
[62] Y. Ueda,et al. Novel Carbapenem Antibiotics for Parenteral and Oral Applications: In Vitro and In Vivo Activities of 2-Aryl Carbapenems and Their Pharmacokinetics in Laboratory Animals , 2012, Antimicrobial Agents and Chemotherapy.
[63] J. Dillon,et al. Two decades of the gonococcal antimicrobial surveillance program in South America and the Caribbean: challenges and opportunities , 2013, Sexually Transmitted Infections.
[64] S. Chisholm,et al. High-Level Azithromycin Resistance Occurs in Neisseria gonorrhoeae as a Result of a Single Point Mutation in the 23S rRNA Genes , 2010, Antimicrobial Agents and Chemotherapy.
[65] I. Kobayashi,et al. Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population , 2007, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[66] P. Barry,et al. The use of cephalosporins for gonorrhea: the impending problem of resistance. , 2009, Expert opinion on pharmacotherapy.
[67] M. Unemo,et al. Two cases of verified clinical failures using internationally recommended first-line cefixime for gonorrhoea treatment, Norway, 2010. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[68] M. Yasuda,et al. Threat to Cefixime Treatment for Gonorrhea , 2007, Emerging infectious diseases.
[69] R. Kirkcaldy,et al. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis , 2012, Postgraduate Medical Journal.
[70] K. Kuroiwa,et al. The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[71] S. Manzano,et al. A New Multidrug-Resistant Strain of Neisseria gonorrhoeae in Australia. , 2015, The New England journal of medicine.
[72] M. Ohnishi,et al. Polymerase chain reaction-based screening for the ceftriaxone-resistant Neisseria gonorrhoeae F89 strain. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[73] K. Holmes,et al. Uptake and Population-Level Impact of Expedited Partner Therapy (EPT) on Chlamydia trachomatis and Neisseria gonorrhoeae: The Washington State Community-Level Randomized Trial of EPT , 2015, PLoS medicine.
[74] Hilary A. Godwin,et al. Stemming the tide of drug-resistant Neisseria gonorrhoeae: the need for an individualized approach to treatment. , 2015, The Journal of antimicrobial chemotherapy.
[75] M. Unemo,et al. Antimicrobial Resistance and Molecular Typing of Neisseria gonorrhoeae Isolates in Kyoto and Osaka, Japan, 2010 to 2012: Intensified Surveillance after Identification of the First Strain (H041) with High-Level Ceftriaxone Resistance , 2013, Antimicrobial Agents and Chemotherapy.
[76] G. D. Walker,et al. Spectinomycin as initial treatment for gonorrhoea. , 1984, British medical journal.
[77] W. Levine,et al. Drugs of choice for the treatment of uncomplicated gonococcal infections. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[78] M. Unemo,et al. Phylogenomics for drug-resistant Neisseria gonorrhoeae. , 2014, The Lancet. Infectious diseases.
[79] D. Livermore,et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? , 2010, The Journal of antimicrobial chemotherapy.
[80] J. Marschall,et al. Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort. , 2012, Clinical therapeutics.
[81] Haruo Watanabe,et al. Spread of a Chromosomal Cefixime-Resistant penA Gene among Different Neisseria gonorrhoeae Lineages , 2009, Antimicrobial Agents and Chemotherapy.
[82] G. Basarab,et al. In Vitro Antibacterial Activity of AZD0914, a New Spiropyrimidinetrione DNA Gyrase/Topoisomerase Inhibitor with Potent Activity against Gram-Positive, Fastidious Gram-Negative, and Atypical Bacteria , 2014, Antimicrobial Agents and Chemotherapy.
[83] H. Palmer,et al. Emergence and spread of azithromycin-resistant Neisseria gonorrhoeae in Scotland. , 2008, The Journal of antimicrobial chemotherapy.
[84] D. Lewis. The Gonococcus fights back: is this time a knock out? , 2010, Sexually Transmitted Infections.
[85] M. Unemo,et al. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance. , 2014, The Journal of antimicrobial chemotherapy.
[86] M. Unemo,et al. Four treatment failures of pharyngeal gonorrhoea with ceftriaxone (500 mg) or cefotaxime (500 mg), Sweden, 2013 and 2014. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[87] M. Yasuda,et al. A single 2 g oral dose of extended-release azithromycin for treatment of gonococcal urethritis. , 2014, The Journal of antimicrobial chemotherapy.
[88] K. Workowski,et al. Update on the management of gonorrhea in adults in the United States. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[89] Direct detection of markers associated with Neisseria gonorrhoeae antimicrobial resistance in New Zealand using residual DNA from the Cobas 4800 CT/NG NAAT assay , 2014, Sexually Transmitted Infections.
[90] D. Schlossberg,et al. Multicenter Trial of Single‐Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea , 1994, Sexually transmitted diseases.
[91] P. Butcher,et al. Point-of-care antibiotic susceptibility testing for gonorrhoea: improving therapeutic options and sparing the use of cephalosporins , 2010, Sexually Transmitted Infections.
[92] D. Whiley,et al. Reduced susceptibility to ceftriaxone in Neisseria gonorrhoeae is associated with mutations G542S, P551S and P551L in the gonococcal penicillin-binding protein 2. , 2010, The Journal of antimicrobial chemotherapy.
[93] D. Klepacki,et al. Binding and Action of CEM-101, a New Fluoroketolide Antibiotic That Inhibits Protein Synthesis , 2010, Antimicrobial Agents and Chemotherapy.
[94] G. Horsman,et al. Molecular Assay for Detection of Genetic Markers Associated with Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae , 2015, Journal of Clinical Microbiology.
[95] J. Papp,et al. Trends in antimicrobial resistance in Neisseria gonorrhoeae in the USA: the Gonococcal Isolate Surveillance Project (GISP), January 2006–June 2012 , 2013, Sexually Transmitted Infections.
[96] M. Unemo,et al. Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. , 2013, The Journal of antimicrobial chemotherapy.
[97] M. Unemo,et al. The European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP)—a sentinel approach in the European Union (EU)/European Economic Area (EEA) , 2013, Sexually Transmitted Infections.
[98] D. Lewis. Will targeting oropharyngeal gonorrhoea delay the further emergence of drug-resistant Neisseria gonorrhoeae strains? , 2015, Sexually Transmitted Infections.
[99] Monica Lahra,et al. Gonococcal antimicrobial resistance in the Western Pacific Region , 2013, Sexually Transmitted Infections.
[100] M. Unemo,et al. High In Vitro Activity of the Novel Spiropyrimidinetrione AZD0914, a DNA Gyrase Inhibitor, against Multidrug-Resistant Neisseria gonorrhoeae Isolates Suggests a New Effective Option for Oral Treatment of Gonorrhea , 2014, Antimicrobial Agents and Chemotherapy.
[101] M. Huband,et al. Characterization of the Novel DNA Gyrase Inhibitor AZD0914: Low Resistance Potential and Lack of Cross-Resistance in Neisseria gonorrhoeae , 2014, Antimicrobial Agents and Chemotherapy.
[102] K. Holmes,et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[103] Kh Yang,et al. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials , 2012, International journal of STD & AIDS.
[104] I. Martin,et al. Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian Sexually Transmitted Infection Clinics, 2010–2013 , 2015, Sexually transmitted diseases.
[105] Kyungwon Lee,et al. Various penA mutations together with mtrR, porB and ponA mutations in Neisseria gonorrhoeae isolates with reduced susceptibility to cefixime or ceftriaxone. , 2010, The Journal of antimicrobial chemotherapy.
[106] M. Unemo,et al. Emergence and evolution of internationally disseminated cephalosporin-resistant Neisseria gonorrhoeae clones from 1995 to 2005 in Japan , 2015, BMC Infectious Diseases.
[107] M. Unemo,et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. , 2011, The Journal of antimicrobial chemotherapy.
[108] J. Bates,et al. Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Australia. , 2014, The Journal of antimicrobial chemotherapy.
[109] F. Hu,et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. , 2004, Diagnostic microbiology and infectious disease.
[110] I. Morrissey,et al. The MUT056399 Inhibitor of FabI Is a New Antistaphylococcal Compound , 2011, Antimicrobial Agents and Chemotherapy.
[111] L. Barbee. Preparing for an era of untreatable gonorrhea , 2014, Current opinion in infectious diseases.
[112] T. Ueshima,et al. In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. , 2014, International journal of antimicrobial agents.
[113] J. Papp,et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[114] D. Stein,et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. , 1987, The New England journal of medicine.
[115] Strategies and laboratory methods for strengthening surveillance of sexually transmitted infections 2012 , 2022 .
[116] T. Tbd. Prospects of untreatable gonorrhea and ways forward , 2016 .
[117] Julian Parkhill,et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: a retrospective observational study , 2014, The Lancet. Infectious diseases.
[118] K. Workowski,et al. Sexually transmitted diseases treatment guidelines, 2015. , 2015, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[119] C. Deal,et al. Vaccine research for gonococcal infections: where are we? , 2013, Sexually Transmitted Infections.
[120] Ronald N. Jones,et al. Activity of JNJ-Q2, a novel fluoroquinolone, tested against Neisseria gonorrhoeae, including ciprofloxacin-resistant strains. , 2012, Diagnostic microbiology and infectious disease.
[121] Monica Lahra,et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. , 2012, The Journal of antimicrobial chemotherapy.
[122] D. Livermore,et al. Which cephalosporin for gonorrhoea? , 2004, Sexually Transmitted Infections.
[123] M. Yasuda,et al. Treatment of uncomplicated gonococcal urethritis by double-dosing of 200 mg cefixime at a 6-h interval , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.
[124] J. Segreti. Multicenter Trial of Single- Dose Azithromycin vs. Ceftriaxone in the Treatment of Uncomplicated Gonorrhea , 1994 .
[125] U. S. Departme. Antibiotic-resistant strains of Neisseria gonorrhoeae. Policy guidelines for detection, management, and control. , 1987, MMWR supplements.
[126] J. Vázquez,et al. New Mutation in 23S rRNA Gene Associated with High Level of Azithromycin Resistance in Neisseria gonorrhoeae , 2010, Antimicrobial Agents and Chemotherapy.
[127] M. Unemo,et al. Genome Sequencing of a Neisseria gonorrhoeae Isolate of a Successful International Clone with Decreased Susceptibility and Resistance to Extended-Spectrum Cephalosporins , 2012, Antimicrobial Agents and Chemotherapy.
[128] M. Unemo,et al. Antibiotic resistance in Neisseria gonorrhoeae: origin, evolution, and lessons learned for the future , 2011, Annals of the New York Academy of Sciences.
[129] H. Handsfield,et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. , 1991, The New England journal of medicine.
[130] T. Degenhardt,et al. Pharmacokinetics of Solithromycin (CEM-101) after Single or Multiple Oral Doses and Effects of Food on Single-Dose Bioavailability in Healthy Adult Subjects , 2011, Antimicrobial Agents and Chemotherapy.
[131] J. Moran. Treating Uncomplicated Neisseria gonorrhoeae Infections: Is the Anatomic Site of Infection Important? , 1995, Sexually transmitted diseases.
[132] M. Cole,et al. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. , 2014, The Journal of antimicrobial chemotherapy.
[133] M. Unemo,et al. The serious threat of multidrug-resistant and untreatable gonorrhoea: the pressing need for global action to control the spread of antimicrobial resistance, and mitigate the impact on sexual and reproductive health , 2012, Sexually Transmitted Infections.
[134] M. Unemo,et al. In Vitro Activity of the New Fluoroketolide Solithromycin (CEM-101) against a Large Collection of Clinical Neisseria gonorrhoeae Isolates and International Reference Strains, Including Those with High-Level Antimicrobial Resistance: Potential Treatment Option for Gonorrhea? , 2012, Antimicrobial Agents and Chemotherapy.
[135] L. Rice. Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae? , 2015, Sexually Transmitted Infections.